Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
   
Ask the Experts About

Choosing Your MedsChoosing Your Meds
           
Rollover images to visit our other forums!
Recent AnswersAsk a Question
  
  • Email Email
  • Glossary Glossary


Epivir once-daily
Oct 17, 2002

Dr. Young,

Is Epivir now available once-daily in the US? I read about but haven't been able to get it...

I don't understand the dosage - why would Epivir be taken previously one 150 mg pill twice a day, for a total of 300 mg--and now two 300 mg pills once a day, for a total of 600mg?

Thank you!

Response from Dr. Young

Thanks for your question.

Lamivudine (Epivir) is approved by the US FDA and the European drug agency to be taken once daily. The total daily dose is the same when taken twice- or once-daily. Hence, the dose should be 300 mg once-daily.

The current formulation of lamivudine in the US is the 150 mg tablet that you're use to taking. You'd therefore take two, 150 mg tablets.

In Europe, and hopefully soon in the US, a 300 mg tablet is available.

Hope this clarifies things for you. -BY



Previous
dave, ya tip-toed..
Next
Acute Hiv/Hbv infection

  
  • Email Email
  • Glossary Glossary

 Get Email Notifications When This Forum Updates or Subscribe With RSS


 
Advertisement



Q&A TERMS OF USE

This forum is designed for educational purposes only, and experts are not rendering medical, mental health, legal or other professional advice or services. If you have or suspect you may have a medical, mental health, legal or other problem that requires advice, consult your own caregiver, attorney or other qualified professional.

Experts appearing on this page are independent and are solely responsible for editing and fact-checking their material. Neither TheBody.com nor any advertiser is the publisher or speaker of posted visitors' questions or the experts' material.

Review our complete terms of use and copyright notice.

Powered by ExpertViewpoint

Advertisement